Entrada Therapeutics (NASDAQ:TRDA) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Entrada Therapeutics (NASDAQ:TRDA) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the company. Guggenheim cut their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Roth Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings lowered Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Entrada Therapeutics Stock Up 1.0%

NASDAQ:TRDA opened at $6.22 on Friday. The firm has a market capitalization of $242.21 million, a PE ratio of -1.57 and a beta of -0.25. Entrada Therapeutics has a 12-month low of $5.55 and a 12-month high of $16.45. The firm has a 50-day moving average price of $6.92 and a 200 day moving average price of $8.59.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. On average, research analysts expect that Entrada Therapeutics will post -4.03 EPS for the current year.

Insider Activity

In other news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the sale, the insider owned 4,318,348 shares of the company’s stock, valued at approximately $30,487,536.88. This trade represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the transaction, the insider owned 3,885,115 shares of the company’s stock, valued at $27,700,869.95. This trade represents a 0.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 946,961 shares of company stock worth $6,725,291 over the last ninety days. Insiders own 9.49% of the company’s stock.

Hedge Funds Weigh In On Entrada Therapeutics

Several institutional investors have recently bought and sold shares of the business. 5AM Venture Management LLC acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at $29,854,949. BlackRock Inc. acquired a new position in Entrada Therapeutics during the 2nd quarter worth about $19,013,000. Nantahala Capital Management LLC acquired a new position in Entrada Therapeutics during the 2nd quarter worth about $2,212,232. Baker BROS. Advisors LP lifted its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after buying an additional 206,911 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Entrada Therapeutics during the 2nd quarter worth about $648,000. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc is a biotechnology company focused on developing medicines designed to address diseases caused by dysfunctional proteins inside cells. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic molecules into target cells and help them escape endosomes, cellular compartments that can limit the activity of certain treatments.

Entrada is applying the EEV platform to oligonucleotide-based medicines, including compounds designed to modify RNA and influence the production of disease-associated proteins.